We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novo Nordisk (PK) | USOTC:NONOF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.358 | -0.27% | 131.142 | 130.01 | 135.67 | 137.34 | 128.64 | 137.34 | 382,916 | 20:45:49 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
Specialized Disclosure Report
NOVO NORDISK A/S | |||
(Exact name of the registrant as specified in its charter) | |||
The Kingdom of Denmark | 333-82318 | N/A | |
(State or other jurisdiction of Incorporation or organization) |
(Commission File Number) |
(IRS Employer Identification No.) | |
Novo Allé, DK-2880 Bagsværd, Denmark | N/A | ||
(Address of principal executive offices) | (Zip code) | ||
Karsten Munk Knudsen | +45 4444 8888 | ||
(Name and telephone number, including area code, of the person to contact in connection with this report.) | |||
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies: |
☒ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2022. |
Section 1 - Conflict Minerals Disclosure
Items 1.01 and 1.02 Conflict Minerals Disclosure and Report, Exhibit
Conflict Minerals Disclosure
A copy of Novo Nordisk A/S’s Conflict Minerals Report for the year ended December 31, 2022 is provided as Exhibit 1.01 hereto and is publicly available at: https://www.novonordisk.com/sustainable-business/performance-on-tbl/more-about-how-we-work-and-report/transparency-disclosures.html
Section 2 – Exhibits
Item 2.01 Exhibits
Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
Date: May 23, 2023 | NOVO NORDISK A/S | |
By: | /s/ Karsten Munk Knudsen | |
Name: | Karsten Munk Knudsen | |
Title: | Executive Vice President & Chief Financial Officer |
1 Year Novo Nordisk (PK) Chart |
1 Month Novo Nordisk (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions